SCHEMBL936825

SCHEMBL936825

C#Cc1ccc2cc3cc(OC)ccc3cc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.50
CYP1A2 P05177 2/20 0.50
NQO1 P15559 1/20 0.46
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
RAB9A P51151 2/20 0.43
HPGDS O60760 1/20 0.42
KDM4E B2RXH2 1/20 0.42
GSTP1 P09211 1/20 0.42
NCF1 P14598 1/20 0.41
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
PTGS1 P23219 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
NPC1 O15118 1/20 0.39
CASP3 P42574 1/20 0.39
SENP7 Q9BQF6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL936832 0.96 CYP2A6 (0.54) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL29566280 0.96 CYP2A6 (0.54) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL29203830 0.83 CYP1A1 (0.50) CYP3A4
SCHEMBL29566275 0.83 CYP2A6 (0.48) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL6891918 0.81 CYP1A2 (0.71) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL7452675 0.81 CYP1A2 (0.71) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL2249185 0.81 CYP1A2 (0.71) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL7451812 0.81 CYP1A2 (0.71) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL7456084 0.81 CYP1A2 (0.71) CYP2A6CYP1A2NQO1HSD17B1HSD17B2
SCHEMBL29919511 0.81 CYP1A2 (0.71) CYP2A6CYP1A2NQO1HSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011009934-A1 TRIS(1,2,3-TRIAZOL-4-YL)METHANE ORGANOMETALLIC COMPOUNDS AS CATALYSTS AND PROCESSES USING THEM. INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA (ICIQ) (ES) 2011-01-27 WO disclosed
US-20090069569-A1 CYCLOADDITION OF AZIDES AND ALKYNES INSTITUT CATALA D'INVESTIGACIO QUIMICA (ES) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069569-A1 CYCLOADDITION OF AZIDES AND ALKYNES PF4, AFF4, FLI1 CYP2A6 238/4885CYP1A2 325/4885NQO1 1400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.